A survey on consciousness towards the proper use of metformin and medical cost in Japanese patients with type 2 diabetes

Yoshitaka Hashimoto,¹ Hisami Yasuzawa,² Tsutomu Ishida,² Yuichi Miyazaki,² and Michiaki Fukui¹*¹

¹Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
²Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd., 35 Higashisotobori-cho, Higashi-ku, Nagoya, Aichi 461-8631, Japan

(Received 9 January, 2021; Accepted 11 February, 2021)

To investigate the patients’ consciousness regarding the use of metformin and medical cost in Japanese patients with type 2 diabetes taking metformin. This cross-sectional study investigated patients’ general characteristics and consciousness regarding medical cost, kidney function, liver function, and metformin usage, using a self-administered, internet-based questionnaire. Among 1,000 patients, 81.0% felt unsatisfied with treatment for type 2 diabetes, with the main reason for dissatisfaction being high medical cost, with 540 patients reporting this. In addition, 16.8% of patients experienced treatment disruption and among them, 48.2% (81/168) answered that the reason was high medical cost. Over half of the patients did not understand their kidney and liver functions, respectively. Only 8.9% and 7.1% of patients knew both the words and meanings behind sick days and lactic acidosis, respectively. In conclusion, many patients with type 2 diabetes taking metformin were not satisfied with their treatments, with the main reason being high medical cost. Moreover, they did not have sufficient knowledge of sick days and/or lactic acidosis.

Key Words: awareness, health literacy, type 2 diabetes, survey, patient’s care

People with type 2 diabetes (T2D) are now increasing in number all over the world. To prevent diabetic complications, maintaining a good blood glucose level is required. Lifestyle management, including regular exercise and proper diet, are the main treatments; however, in patients with T2D, it is difficult to achieve a good blood glucose level using these treatments. Thus, to achieve a good blood glucose level, many patients with T2D receive a pharmacologic therapy. The medical cost for diabetes mellitus has been increasing in Japan. Thus, it has been advocated to suppress medical cost.

Metformin is used in many countries as the first-line drug for the treatment of T2D because of its price, safety, and protective effects on cardiovascular disease (CVD). On the other hand, dipeptidyl peptidase-4 (DPP4) inhibitors are chosen as the first choice in Japan. One of the possible reasons why metformin is not chosen as the first choice is an excessive concern for lactic acidosis. In the past, the use of metformin was limited by several contraindications to avoid lactic acidosis; however, based on the latest scientific findings on the safety of metformin, the restrictions on its use have been revised. Currently, moderate renal dysfunction [estimated glomerular filtration rate (eGFR) >30 to 60 mL/min/1.73 m²] is no longer a contraindication to the use of metformin in Japan. According to recommendations from the Japan Diabetes Society and the Japan Association for Diabetes Education and Care, patients with severe renal dysfunction, severe cardiovascular and pulmonary dysfunction, scheduled surgery, recent surgical history, severe hepatic dysfunction, and conditions that require patient attention (such as dehydration, sick days, and excessive alcohol consumption), are not recommended to use metformin. In order to promote the proper use of metformin, it is necessary that patients have proper knowledge about metformin and their own kidney and liver functions. Further minimizing the risk for lactic acidosis and sick day will require effective dissemination of sick day management recommendations to patients. However, little is known about patients’ consciousness regarding the use of metformin.

Furthermore, clinical inertia, which means treatment goals not being met and adequately reinforced, is also an important problem. Many causes of clinical inertia, including medical cost, have been reported. One of the ways to reduce medical cost is the use of compounding agents. Many combination medications for diabetes are now available in the market. Previous studies revealed that the use of combination medications increased patient adherence. However, little is known about patients’ consciousness regarding medical cost and the combination medication.

Thus, the purpose of this cross-sectional study was to investigate patient consciousness regarding the use of metformin and medical cost in Japanese T2D patients taking metformin by using an internet survey.

Materials and Methods

Study design and participants. This cross-sectional study is based on data from a self-administered, internet-based questionnaire for Japanese T2D patients taking metformin. The internet-based questionnaire was conducted by Asmarca Co., Ltd. (Tokyo, Japan). The questionnaire was distributed to registered members of Asmarca’s survey panel (D-style web). Informed consent was always obtained from all the registered members at the time of registration. The selection criteria were patients aged 16 years or older who were currently diagnosed and treated for T2D with metformin-containing medications (Metgluco tablets, Glycoran tablets, metformin hydrochloride tablets MT, Metact combination tablets, Equemet combination tablets, Inisync combination tablets, and Metoana combination tablets). The patients were enrolled by region (Hokkaido/Tohoku, Kanto, Chubu, Kinki, Chugoku/Shikoku, and Kyushu/Okinawa) according to the proportion of the population in the region. The survey was conducted from December 20, 2019 and finished December 26, 2019.

*To whom correspondence should be addressed.
E-mail: michiaki@koto.kpu-m.ac.jp

doi: 10.3164/jcbn.21-5
2019, since responses from one thousand participants, the target sample size, were gathered. This study was approved by the ethics committee of the Kyoto Prefectural University of Medicine (ERB-C-1760).

**Questionnaire for general characteristics.** Using the questionnaire, the data of age, sex, place of residence, height, body weight, household income (<2,000,000 JPY, 2,000,000 to <4,000,000 JPY, 4,000,000 to <6,000,000 JPY, 6,000,000 to <8,000,000 JPY, 8,000,000 to <10,000,000 JPY, 10,000,000 JPY or more, or Decline to answer), living conditions (Living alone, With partner only, With families, or Others), job conditions (Employed, Self-employed, Part-time job, or Others), duration of diabetes, number of medications taken for T2D, usage of injections for diabetes (insulin and/or Glucagon-like Peptide 1), type of hospital (Clinic, university hospital, or hospital other than university hospital), type of doctor (Diabetologist, Non-diabetologist, or Unknown), and frequency of forgetting to take medicine [Almost none, Sometimes forget (2–3 days a week), Often forget (more than 4 days a week)] were gathered.

**Questionnaire for consciousness for medical cost for diabetes.** Using the following questionnaire, data on patient awareness of medical costs for diabetes were gathered: 1) Satisfaction with treatment for T2D (Satisfied or Not satisfied); if they answered that they were not satisfied, the reason (high medical cost, need for long-term treatment, not good glycemic control, too much medications, medication side effects, lack of doctor’s explanation, and/or others); 2) percentage co-payment of medical cost (None, 10%, 20%, 30%, or others); 3) monthly medical cost of treatment for T2D divided into four groups (<3,000 JPY, 3,000 to <6,000 JPY, 6,000 to <10,000 JPY, or 10,000 JPY or more); 4) Have you received an explanation from your doctor or pharmacist about the price difference between different medicines (Always received at medication initiation and/or change, received, not received, or Do not remember)? Among the patients other than those who answered that they always received at medication initiation and/or change, would you want to receive an explanation from your doctor or pharmacist about the price difference between different medicines at medication initiation and/or change? (Hope, Not hope, or Either way); 5) Would you like to change to a cheaper medication that has about the same effect? (Yes or No); 6) Experience of treatment disruption? (Yes or No) If they answered yes, the reason was asked to be indicated (high medical cost, burden to visit hospital, not good glycemic control, long waiting times, not seeing the necessity for treatment, not a good fit with the medical staff, and/or others); 7) Are you currently taking a combination medication for the treatment of T2D (Yes, No, or Unknown)? If they answered No or Unknown, do you know combination medications (Yes, or No)? Would you like to change to a combination medication, if recommended by your doctor (Strongly hope, hope, not hope, or either way)?

**Questionnaire for consciousness for kidney functions, liver functions and metformin usage.** A questionnaire was used to ask the participants if they understood their kidney function [Level of kidney function (mild/moderate/severe), eGFR, serum creatinine level, and/or others] and/or liver function [Level of liver function (mild/moderate/severe), Aspartate aminotransferase (AST) level, Alanine aminotransferase (ALT) level, and/or others]. In addition, we asked them if they understood the sick day, using the question “Do you know of sick days, which are days wherein a diabetic patient has a fever, diarrhea, vomiting, or is unable to eat due to loss of appetite during treatment (Known both words and meanings, Known words, Known meanings, or Not known)?” We also asked them if they understood lactic acidosis, using the question “Are you aware of lactic acidosis, which is a rare side effect of metformin that increases lactic acid in the blood and causes the blood to become more acidic (Known words and meanings, Known words, Known meanings, or Not known)?”

The patients were also asked whether they had received the following instructions from their doctor or pharmacist: 1) On a sick day, stop taking the medication that contains metformin and talk to your doctor; 2) if symptoms of lactic acidosis appear, visit the hospital; 3) Do not drink too much alcohol; 4) Drink a proper amount of water, and 5) Inform your doctor before undergoing of any tests that use iodine contrast agents, such as angiography, urography, or CT scans. Questions about sick days 1) and lactic

---

**Table 1. Clinical characteristics of study participants**

| Age, years | Total n = 1,000 | Mean ± SD, n (%) |
|------------|-----------------|-----------------|
| Age group  |                 |                 |
| ≤50        | 162 (16.2%)     |                 |
| 51–64      | 440 (44.0%)     |                 |
| ≥65        | 398 (39.8%)     |                 |
| Sex        |                 |                 |
| Men        | 868 (86.8%)     |                 |
| Women      | 132 (13.2%)     |                 |
| Height, cm | 167.6 ± 7.5     |                 |
| Weight, kg | 70.3 ± 14.1     |                 |
| Body mass index, kg/m² | 25.0 ± 4.4 |                 |
| Household income |          |                 |
| <2,000,000 JPY | 113 (11.3%) |                 |
| 2,000,000 to <4,000,000 JPY | 249 (24.9%) |                 |
| 4,000,000 to <6,000,000 JPY | 195 (19.5%) |                 |
| 6,000,000 to <8,000,000 JPY | 151 (15.1%) |                 |
| 8,000,000 to <10,000,000 JPY | 77 (7.7%) |                 |
| 10,000,000 JPY or more | 108 (10.8%) |                 |
| Decline to answer | 107 (10.7%) |                 |
| Living conditions |          |                 |
| Living alone | 176 (17.6%) |                 |
| With partner only | 355 (35.5%) |                 |
| With families | 454 (45.4%) |                 |
| Others | 15 (1.5%) |                 |
| Job conditions |          |                 |
| Employed | 402 (40.2%) |                 |
| Self-employed | 111 (11.1%) |                 |
| Part-time job | 74 (7.4%) |                 |
| Others | 413 (41.3%) |                 |
| Duration of diabetes, years | 12.5 ± 8.6 |                 |
| Number of medications taken for T2D | 3.0 ± 2.0 |                 |
| Usage of injections (insulin and/or GLP-1) |          |                 |
| Yes | 232 (23.2%) |                 |
| No | 768 (76.8%) |                 |
| Hospital types |          |                 |
| Clinic | 703 (70.3%) |                 |
| University hospital | 72 (7.2%) |                 |
| Hospital other than university hospital | 225 (22.5%) |                 |
| Type of doctor |          |                 |
| Diabetologist | 525 (52.5%) |                 |
| Non-diabetologist | 429 (42.9%) |                 |
| Unknown | 46 (4.6%) |                 |
| Frequency of forgetting to take medicine |          |                 |
| Almost none | 874 (87.4%) |                 |
| Sometimes forget (2–3 days a week) | 118 (11.8%) |                 |
| Often forget (more than 4 days a week) | 8 (0.8%) |                 |

GLP-1, glucagon-like Peptide 1; T2D, type 2 diabetes.
acidity 2) were asked to the patients other than those who were unaware about sick days and lactic acidosis, respectively.

**Statistical analysis.** Statistical analysis was conducted by Sugimoto Data Analysis Service. The mean (SD) or frequencies of potential confounding variables were expressed.

To clarify the differences among age groups, we divided the patients into three groups according to age (≤50, 51-64, and ≥65 years). The differences among groups were evaluated using the chi-squared test or one-way ANOVA. In addition, the Tukey-Kramer method or Bonferroni’s multiple comparison test was used for multiple comparisons. Statistical significance was set at \(p<0.05\).

**Results**

This study included 1,000 Japanese T2D patients taking metformin. The general characteristics of the study participants are described in Table 1. The mean (SD) age, duration of diabetes, and body mass index were 60.7 (10.6) years, 12.5 (8.6) years, and 25.0 (4.4) kg/m², respectively. The mean number of medications used for T2D was 3.0 (2.0), while 23.2% of patients used injection. A total of 70.3% of patients were treated in clinics, while 29.7% of patients were treated in hospitals (including university hospitals). Moreover, 52.5% of patients received treatment by a diabetologist. In total, 87.4% of patients took all medications daily, with high medication adherence.

Figure 1 and Table 2 show the results of consciousness about medical cost. Surprisingly, 81.0% of them felt unsatisfied with their current treatment for T2D, with the main reason for dissatisfaction being high medical cost, which accounted for 54.0% \((n = 540)\) (Fig. 1). In addition, 72.4% \((n = 168)\) of patients who received an injection for diabetes \((n = 232)\) were unsatisfied with treatment for T2D due to high medical costs. In contrast, 48.4% \((n = 372)\) of patients who did not receive an injection \((n = 768)\) were unsatisfied for the same reason (Fig. 2). The monthly medical cost of treatment for T2D showed that 49.9% of them used over 6,000 JPY per month for medical costs (Table 2). Among patients with a monthly medical cost of 6,000 JPY or more \((n = 499)\), 70.3% \((n = 351)\) were unsatisfied with treatment for T2D due to high medical costs. In contrast, 37.7% \((n = 189)\) of patients with a monthly medical cost of less than 6,000 JPY \((n = 501)\) were unsatisfied for the same reason (Fig. 2). On the other hand, only 26.8% of patients always received an explanation for differences in drug prices at medication initiation and/or change, and 76.8% of patients wanted to change to a cheaper medication. In addition, 16.8% of patients experienced treatment disruption. Among these patients \((n = 168)\), 48.2% \((n = 81)\) answered that the reason for treatment disruption was high medical cost. 17.3% \((n = 29)\) did not feel the necessity for treatment, and 15.5% \((n = 26)\) did not fit well with the medical staff. Moreover, 41.2% of patients were currently taking combination medication for the treatment of T2D, while 48.9% of them did not know what a combination medication is. Among patients who received treatment by a diabetologist \((n = 525)\), 42.3% \((n = 222)\) were taking combination medications for the treatment of T2D, while 41.3% \((n = 177)\) of patients who received treatment by a non-diabetologist \((n = 429)\) were taking combination medications as well. Among patients who were not taking combination medications \((n = 588)\), 59.5% \((n = 350)\) wanted to change to combination medications.

Table 3 shows the results of consciousness regarding kidney function, liver function, and metformin usage. Only 45.7% and 47.4% of patients understood their kidney and liver functions, respectively. Surprisingly, only 8.9% of them knew both the words and meanings behind sick days, and only 7.1% knew those of lactic acidosis. Only 9.7% of patients were told to stop taking the medication that contains metformin on a sick day and to talk to their doctor. Only 8.7% of patients were told to visit the hospital if symptoms of lactic acidosis appeared. Figure 3 shows the knowledge of sick days and lactic acidosis stratified by the duration of diabetes or injection usage. Among patients with a duration of diabetes equal to 11 years or more \((n = 486)\), 84.0% \((n = 408)\) did not know about sick days and 88.3% \((n = 429)\) did not know of lactic acidosis. In contrast, 73.5% \((n = 378)\) of patients with a duration of diabetes less than 11 years \((n = 514)\) did not know about sick days and lactic acidosis, respectively. Moreover, among patients with injection usage \((n = 232)\), 53.4% \((n = 124)\) did not know about sick days and 62.9% \((n = 146)\) did not know of lactic acidosis; among patients without injection usage \((n = 768)\), 86.2% \((n = 662)\) did not know about sick days and 86.1% \((n = 661)\) did not know of lactic acidosis.

The differences among age groups are shown in Supplemental Table 1-3*. The percentage of patients not satisfied with the treatment for T2D in patients aged <50 years was higher than that of patients in the other age groups. The reason for their dissatis-

---

*See online. https://doi.org/10.3164/jcbn.21-5  
Y. Hashimoto et al.*
Table 2. The results of consciousness for medical cost for diabetes

| Total n = 1,000 | n (%) |
|-----------------|-------|
| **Satisfaction with treatment for T2D** | |
| Satisfied | 190 (19.0%) |
| Not satisfied | 810 (81.0%) |
| **The reason for not satisfied (Multiple selections possible)** | |
| High medical cost | 540 (54.0%) |
| Need for long-term treatment | 506 (50.6%) |
| Not good glycemic control | 373 (37.3%) |
| Too much medications | 263 (26.3%) |
| Medication side effects | 58 (5.8%) |
| Lack of doctor’s explanation | 54 (5.4%) |
| Others | 29 (2.9%) |
| **Percentage co-payment of medical cost** | |
| None | 29 (2.9%) |
| 10% | 86 (8.6%) |
| 20% | 151 (15.1%) |
| 30% | 726 (72.6%) |
| Others | 8 (0.8%) |
| **Monthly medical cost of treatment for T2D** | |
| <3,000 JPY | 166 (16.6%) |
| 3,000 to <6,000 JPY | 335 (33.5%) |
| 6,000 to <10,000 JPY | 230 (23.0%) |
| 10,000 JPY or more | 269 (26.9%) |
| **Have you received an explanation from your doctor or pharmacist about the price difference between different medicines?** | |
| Always received at medication initiation and/or change | 268 (26.8%) |
| Received | 305 (30.5%) |
| Not received | 358 (35.8%) |
| Do not remember | 69 (6.9%) |
| **Would you want to receive an explanation from your doctor or pharmacist about the price difference between different medicines at medication initiation and/or change?** | |
| I’ve already received an explanation | 268 (26.8%) |
| Hope | 405 (40.5%) |
| Not hope | 85 (8.5%) |
| Either way | 242 (24.2%) |
| **Would you like to change to a cheaper medication that has about the same effect?** | |
| Yes | 768 (76.8%) |
| No | 232 (23.2%) |
| **Experience of treatment disruption** | |
| No | 832 (83.2%) |
| Yes | 168 (16.8%) |
| **Reasons for treatment disruption (Multiple selections possible)** | |
| High medical cost | 81 (8.1%) |
| Burden to visit hospital | 63 (6.3%) |
| Not good glycemic control | 54 (5.4%) |
| Long waiting times | 30 (3.0%) |
| Not seeing the necessity for treatment | 29 (2.9%) |
| Not a good fit with the medical staff | 26 (2.6%) |
| Others | 12 (1.2%) |
| **Are you currently taking combination medication for the treatment of T2D?** | |
| Yes | 412 (41.2%) |
| No | 480 (48.0%) |
| Unknown | 108 (10.8%) |
| **Do you know combination medications?** | |
| I’ve already taken combination medication for the treatment of T2D | 412 (41.2%) |
| Yes | 99 (9.9%) |
| No | 489 (48.9%) |
| **Would you want to change to combination medication, if your doctor recommends?** | |
| I’ve already taken combination medication for the treatment of T2D | 412 (41.2%) |
| Strongly hope | 90 (9.0%) |
| Hope | 260 (26.0%) |
| Not hope | 48 (4.8%) |
| Either way | 190 (19.0%) |

T2D, type 2 diabetes.
Table 3. The results of consciousness for kidney functions, liver functions and metformin usage

| Question                                      | Total n = 1,000 | n (%)   |
|-----------------------------------------------|-----------------|---------|
| Do you know your kidney function?             |                 |         |
| No                                            | 543 (54.3%)     |         |
| Yes                                           | 457 (45.7%)     |         |
| Level of kidney function (mild/moderate/severe)* | 349 (34.9%)     |         |
| eGFR*                                         | 219 (21.9%)     |         |
| Serum creatinine level*                       | 271 (27.1%)     |         |
| Others*                                       | 4 (0.4%)        |         |
| Do you know your liver function?              |                 |         |
| No                                            | 526 (52.6%)     |         |
| Yes                                           | 474 (47.4%)     |         |
| Level of liver function (mild/moderate/severe)* | 315 (31.5%)     |         |
| AST level*                                     | 306 (30.6%)     |         |
| ALT level*                                     | 303 (30.3%)     |         |
| Others*                                       | 20 (2.0%)       |         |
| Do you know of sick days?                     |                 |         |
| Known both words and meanings                 | 89 (8.9%)       |         |
| Known words                                   | 72 (7.2%)       |         |
| Known meanings                                | 53 (5.3%)       |         |
| Not known                                     | 786 (78.6%)     |         |
| Do you know of lactic acidosis?               |                 |         |
| Known both words and meanings                 | 71 (7.1%)       |         |
| Known words                                   | 92 (9.2%)       |         |
| Known meanings                                | 30 (3.0%)       |         |
| Not known                                     | 807 (80.7%)     |         |
| Instruction from your doctor or pharmacist   |                 |         |
| On a sick day, stop taking the medication     |                 |         |
| Yes                                           | 97 (9.7%)       |         |
| No                                            | 117 (11.7%)     |         |
| Not known sick day                           | 786 (78.6%)     |         |
| If symptoms of lactic acidosis appear, visit hospital |         |         |
| Yes                                           | 87 (8.7%)       |         |
| No                                            | 106 (10.6%)     |         |
| Not known lactic acidosis                     | 807 (80.7%)     |         |
| Do not drink too much alcohol                 |                 |         |
| Yes                                           | 407 (40.7%)     |         |
| No                                            | 593 (59.3%)     |         |
| Drink a proper amount of water                |                 |         |
| Yes                                           | 583 (58.3%)     |         |
| No                                            | 417 (41.7%)     |         |
| Inform your doctor before undergoing any tests that use iodine contrast agents | 224 (22.4%) |         |
| Yes                                           | 776 (77.6%)     |         |
| No                                            |                 |         |

eGFR, estimated glomerular filtration rate. *Multiple selections possible.
faction is the higher percentage of medical cost in patients aged ≤50 years compared to other age groups. In addition, the percentage of medication side effects and lack of doctors’ explanations were also higher in this specific age group (Supplemental Table 2*). Furthermore, the percentage of experience of treatment disruption in patients aged ≤50 years was higher than that in patients in the other age groups (Supplemental Table 2*). On the other hand, the percentages of patients who did not have knowledge of sick day and lactic acidosis increased with age (Supplemental Table 3*).

**Discussion**

This cross-sectional study of an internet survey investigated the patients’ consciousness regarding the use of metformin and medical cost in Japanese T2D patients taking metformin. To avoid the side effects of metformin, knowledge of sick days and lactic acidosis is important. Surprisingly however, about 80% of patients did not have knowledge of sick days and lactic acidosis, respectively. In addition, this study showed that 80% of patients felt unsatisfied with treatment and 16.8% of patients had experiences of treatment disruption, with high medical cost as the main reason for both. Moreover, only about 25% of patients always received an explanation for differences in drug prices at medication initiation and/or change, with about 75% of patients wanting to change to a cheaper medication.

Metformin is used as the first-line drug for the treatment of T2D in many countries* and is considered to be a cost-effective agent. Lactic acidosis is a rare and serious side effect of metformin. To avoid this side effect, the proper use of metformin is needed. In Japan, metformin is contraindicated for use in patients with severe renal dysfunction; its use in patients with moderate renal dysfunction is now possible, but dose adjustment is required. In addition, in Japan, the patient package inserts of metformin-containing products state that administration should be discontinued during sick days and consult your doctor to avoid lactic acidosis.

Thus, to safely use metformin, patients should also have an understanding of their kidney functions and knowledge of sick days* and lactic acidosis. However, little is known about the knowledge of sick days and lactic acidosis in Japanese T2D patients taking metformin. Surprisingly, 80% of patients did not have knowledge about sick days or lactic acidosis. In addition, more than 90% of patients did not know what to do during sick days or lactic acidosis. In particular, patients with a long duration of disease and patients who did not use injections were less likely to have knowledge of sick days or lactic acidosis. Thus, based on these facts, healthcare professionals should provide knowledge of sick days and lactic acidosis for T2D patients taking metformin. Moreover, sub-analysis showed that elderly patients were found to be more lacking in this knowledge. Since elderly patients have a higher risk of sick days and lactic acidosis, healthcare professionals should take special care of elderly patients. It is unclear whether the doctor gave the patient information about sick days or lactic acidosis. In any case, the doctor needs to treat patients with the belief that they do not have an understanding of this information.

**Overcoming clinical inertia is important to achieve treatment goals for diabetes.** Furthermore, it has been reported that treatment satisfaction was associated with improvements of adherence, compliance, and persistence. Many patients felt unsatisfied with treatment, with the main reason being high medical cost. In fact, it needs high cost for treatment diabetes, including usage of insulin, although it has been reported that usage of insulin is effective for glycemic control. Moreover, only 25% of patients always received an explanation of medical costs. One of the solutions to the medical cost might be frequent conversations between doctors and patients about treatment, including explaining medical costs. A previous study showed that many patients point out the importance of having a conversation with a doctor for treatment. Another solution is the use of cheaper medications, such as combination medications. About 75% of patients wanted to change to a cheaper medication. In addition, patients that used injections and patients with monthly medical costs of treatment for T2D 6,000 JPY or more were more likely to feel unsatisfied with their medical costs. About 40% of patients were currently taking a combination medication, suggesting that their use has been widespread, but about 50% of patients still did not know about combination medications. Using these combination medications is useful not only for decreasing

| Not known sick day | All (1,000) | 786 (78.6%) |
|--------------------|-------------|-------------|
| Duration of diabetes | 11 years or more (486) | 408 (84.0%) |
|                  | <11 years (514) | 378 (73.5%) |
| Usage of injections (insulin and/or GLP-1) | Yes (232) | 124 (53.4%) |
|                      | No (768) | 662 (86.2%) |
| Not known lactic acidosis | All (1,000) | 807 (80.7%) |
| Duration of diabetes | 11 years or more (486) | 429 (88.3%) |
|                  | <11 years (514) | 378 (73.5%) |
| Usage of injections (insulin and/or GLP-1) | Yes (232) | 146 (62.9%) |
|                      | No (768) | 661 (86.1%) |

**Fig. 3.** Knowledge of sick days and lactic acidosis stratified by the duration of diabetes or injection usage.

*See online. https://doi.org/10.3164/jcbn.21-5

doi: 10.3164/jcbn.21-5
medical costs, but also for enhancing medication adherence. Medication adherence is reported to be associated with glycemic control, diabetic complications, and overall costs. Thus, the use of combination medications may be effective in overcoming clinical inertia. Furthermore, another solution is to enhance diet and exercise therapies. A previous study showed that these therapies are effective for glycemic control.

In this study, 16.8% of patients answered that experience of treatment disruption, which is almost same as a previous report of 13% from Japan. Treatment disruption is reported to be associated with risk of diabetic complications. The reasons for treatment disruption in patients who experienced treatment disruption suggest that the presentation of medical cost to patients and informed choice are important to prevent treatment disruption. Moreover, sub-analysis showed that younger patients felt unsatisfied with treatment and medical costs. Since younger patients need continued treatment, healthcare professionals should take care more about medical costs and satisfaction with treatment.

We should mention the limitations of this study. First, this was a self-reported questionnaire survey. Thus, there is a possibility of false reporting. Second, many of the participants in this study were men. In addition, there is a possibility of selection bias, although participants were recruited from Asmarq’s survey panel (D style web) that was registered through the general procedure. Lastly, this study included only Japanese people; thus, generalization to non-Japanese is unclear.

In conclusion, patients with T2D taking metformin were not satisfied with their treatments, and the main reason was high medical cost. Moreover, they did not have sufficient knowledge of sick days and/or lactic acidosis.

Abbreviations

CVD cardiovascular disease
DPP4 dipeptidyl peptidase-4
eGFR estimated glomerular filtration rate
T2D type 2 diabetes

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. We affirmed that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned.

Conflict of Interest

HY, TI, and YM are employees of Sanwa Kagaku Kenkyusho Co., Ltd. MF received grants and personal fees from Sanwa Kagaku Kenkyusho Co., Ltd. YH received grants from Asahi Kasei Pharma and personal fees from Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Sanoﬁ K.K., and Daiichi Sankyo Co., Ltd., outside the submitted work. MF received grants from Takeda Pharma Co. Ltd., Sanoﬁ K.K., Kissei Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corp, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co. Ltd., Daiichi Sankyo Co. Ltd., MSD K.K., Kowa Pharma Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharma Co. Ltd., Eli Lilly Japan K.K., Taisho Pharma Co. Ltd., Teijin Pharma Ltd., Nippon Chemiphar Co., Ltd., Johnson & Johnson K.K. Medical Co., Abbott Japan Co. Ltd., and Terumo Corp., and received personal fees from Teijin Pharma Ltd., Arkray Inc., Kissei Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., Sanoﬁ K.K., Takeda Pharma Co. Ltd., Astellas Pharma Inc., MSD K.K., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Daiichi Sankyo Co. Ltd., Kowa Pharma Co. Ltd., Ono Pharma Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Bayer Yakuhin, Ltd., AstaZeneca K.K., Mochida Pharma Co. Ltd., Abbott Japan Co. Ltd., Eli Lilly Japan K.K., Medtronic Japan Co. Ltd., and Nipro Corp. outside the submitted work.

Funding

This study was funded by Sanwa Kagaku Kenkyusho Co., Ltd.

References

1 Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
2 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865.
3 American Diabetes Association. 5. Lifestyle management: Standards of medical care in diabetes-2019. Diabetes Care 2019; 42 (Suppl 1): S46–S60.
4 García-Pérez LE, Alvarez M, Dilla T, Gil-Guilén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013; 4: 175–194.
5 Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–2498.
6 Urakami T, Kubarahara R, Yoshida K. Economic impact of diabetes in Japan. Curr Diab Rep 2019; 19: 2.
7 Kamada T, Kamaru H, Nishimura S, Kohsaka S, Miya T. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators. Curr Med Res Ops 2020; 36: 749–756.
8 Ministry of Health, Labour and Welfare. Review of Contraindications of Metformin including “renal impairment”. Pharmaceuticals and Medical Devices Safety Information 2019; 365: 5–8.
9 Recommendations for proper use of metformin. The Japan Diabetes Society. http://www.jds.or.jp/modules/important/index.php?content_id=20. Accessed 4 Jan 2021. (in Japanese)
10 MacCallum L, Senior PA. Safe use of metformin in adults with type 2 diabetes and chronic kidney disease: Lower dosages and sick-day education are essential. Can J Diabetes 2019; 43: 76–80.
11 Khunti K, Davies MJ. Clinical inertia—Time to reappraise the terminology? Prim Care Diabetes 2017; 11: 105–106.
12 Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther 2018; 35: 1735–1745.
13 Leichter SB, Thomas S. Combination medications in diabetes care: an opportunity that merits more attention. Clin Diabetes 2003; 21: 175–178.
14 Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008; 23: 611–614.
15 Bauwarter A, Drame K, Geutjens S, Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics 2020; 12: 190.
16 Vaidya V, Anupindi VR, Pinto S, Kaun M. Cost utility analysis of fixed-dose and free-dose combinations of oral medications in type 2 diabetes patients. J Pharm Heal Serv Res 2016; 7: 181–187.
17 Hanatani T, Sai K, Tohkin M, Segawa K, Saito Y. Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. Int J Clin Pharm 2015; 37: 537–545.
18 Reach G, Pechter V, Gentilleva R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab 2017; 43: 501–511.

Y. Hashimoto et al. J. Clin. Biochem. Nutr. | Published online: 7 May 2021 | 7
Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. *Patient Prefer Adherence* 2012; 6: 39–48.

Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. *Diabetes Res Clin Pract* 2010; 87: 204–210.

Zhang W, Tang Y, Huang J, Yang Y, Yang Q, Hu H. Efficacy of inulin supplementation in improving insulin control, HbA1c and HOMA-IR in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *J Clin Biochem Nutr* 2020; 66: 176–183.

Kubo T, Okuyama K, Zhao X, *et al*. Factors associated with reluctance to initiate or continue oral antihyperglycemic agent (OAHA) treatments in type 2 diabetes mellitus patients in Japan: an observational patient-reported study. *Diabetes Metab Syndr Clin Res Rev* 2019; 13: 1201–1207.

McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* 2018; 20: 1040–1043.

Hua L, Lei M, Xue S, Li X, Li S, Xie Q. Effect of fish oil supplementation combined with high-intensity interval training in newly diagnosed non-obese type 2 diabetes: a randomized controlled trial. *J Clin Biochem Nutr* 2020; 66: 146–151.

Tanaka M, Ito H, Nemoto A, *et al*. Relationship between the history of intermittent treatment for type 2 diabetes mellitus and the risk of diabetic vascular complications. *J Japan Diab Soc* 2015; 58: 100–108. (in Japanese)

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/).